Our lead programs are focused in the areas of precision medicine oncology, immuno-oncology, inflammation, fibrosis with other indications to come as the platform continues to mature. f5 Therapeutics places a premium on tackling highly prevalent diseases with no treatment options, such as NASH. Our goal is to develop our extensive pipeline through early-stage Phase 1 proof of concept via partnerships with global leaders in each therapeutic category.
Oncology
Wnt-Dependent Disease: β-catenin -driven liver cancer represents 30% of all hepatocellular carcinoma (HCC) and are characterized by a suppressive or “cold” immune cell microenvironment limiting checkpoint therapy effectiveness.
NK Activation Program: The presence of Natural Killer cells within a tumor has been associated with a favorable prognosis in cancer and but show decreased activity in the immune suppressive tumor microenvironment (TME). A potential mechanism to restore NK cell activity is degradation of known, transcriptional repressor neosubstrates.
Local activation of TNF-α: TNF-α plays a critical role in tumor signaling pathways and immune cell manipulation within the tumor microenvironment (TME). Because TNF-α induces diverse effects in TME, both oncogenic and tumor-suppressive effects, this makes it an ideal target to try and induce the anti-tumor effect to improve treatment efficacy in patients with TNF-α sensitive cancers.